Search results for "nimet"
showing 10 items of 108 documents
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafen…
2020
Abstract Background BRAF/MEK inhibitor combinations are established treatments for BRAF V600–mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up. Methods In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600–mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib …
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
2017
Korpusonomastinen tutkimus slanginimistä Hesa ja Stadi digitaalisissa diskursseissa
2019
Artikkelissamme selvitämme Helsinkiä tarkoittavien slanginimien, Hesan ja Stadin, käyttöä uudentyyppisen aineiston ja menetelmän avulla. Aiemmissa näitä nimiä koskevissa tutkimuksissa lähtökohta on ollut kvalitatiivinen, mutta tässä tutkimuksessa lähdemme liikkeelle laajasta digitaalisesta aineistosta ja tilastollisista menetelmistä. Tutkimuksemme on uusi avaus nimistöntutkimuksessa, ja nimitämme sitä korpusavusteiseksi nimistöntutkimukseksi, lyhyemmin korpusonomastiikaksi.
 Aineistonamme on laaja Suomi24-keskustelufoorumista muodostettu ja Kielipankista saatava Suomi24-korpus, josta olemme hakeneet Hesa- ja Stadi-nimet. Tutkimus toteutetaan korpusavusteisena diskurssintutkimuksena. Mo…
Extracting locations from sport and exercise-related social media messages using a neural network-based bilingual toponym recognition model
2022
Funding: This study is a part of the “Equality in suburban physical activity environments, YLLI” research project (in Finnish: Yhdenvertainen liikunnallinen lähiö, YLLI). The project is being financed by the research program about suburban in Finland “Lähiöohjelma 2020-2022” coordinated by the Ministry of Environment (grant recipient: Dr. Petteri Muukkonen). Sport and exercise contribute to health and well-being in cities. While previous research has mainly focused on activities at specific locations such as sport facilities, “informal sport” that occur at arbitrary locations across the city have been largely neglected. Such activities are more challenging to observe, but this challenge may…
El tribunal del repeso y la planimetría urbana de Valencia (1776-1794)
2014
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomis…
2017
Summary Background Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF V600 -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAF V600 -mutant melanoma. Methods COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a B…
Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study
2017
AIM To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was …
Comparison of the planimetry and point-counting methods for the assessment of the size of the mandible cysts on orthopantomograms
2011
Sahin, Bunyamin/0000-0001-8538-8443 WOS: 000304343300015 PubMed: 22143725 Objective: The purpose of this study is to compare the computer-assisted planimetry and point-counting methods in evaluating the sizes of the mandibular cysts with respect to their agreement and the time required to analyze. Study Design: The surface areas of 46 mandibular cyst lesions on orthopantomograms were estimated using the point-counting and computer-assisted planimetry methods. Three observers evaluated the outlined areas twice, using the point-counting (PC) and computer-assisted planimetry (CAP) methods with an interval of two weeks. In the planimetry technique, digitalized images and ImageJ software were us…
Suomalaisen perheen yhteisen sukunimen lyhyt historia
2016
Viimeistään 1900-luvulta lähtien on ajateltu, että yhteinen sukunimi symboloi suomalaista perhettä julkisissa yhteyksissä ja muodostaa perheenjäsenten yhteisen identiteetin perustekijän. Suomen lainsäädännön mukaan naiset olivat kuitenkin velvollisia ottamaan aviomiehensä sukunimen vain lyhyen aikaa, 1930-luvulta 1980-luvulle ulottuvalla ajanjaksolla. Pohdin artikkelissani, miksi 1800-luvun lopun ja 1900-luvun alkuvuosikymmenten ajatusmaailma vaikutti hyvin pitkään suomalaisten sukunimistöön. peerReviewed
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
2019
Abstract Background Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used. The objective of this study was to fully describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK inhibitor combination encorafenib+binimetinib. Patients and methods Patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma were randomised to receive encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, encorafenib 300 mg on…